Возможны противопоказания. Необходимо ознакомиться с инструкцией или проконсультироваться со специалистом РУССКИЙ    ENGLISH



Unique pharmaceutical preparation MYRAMISTIN® was developed within the Space Biotechnology Programme. One of the Programme's objectives was to find and develop a new preparation which would effectively fight most pathogenic microorganisms and act so that they would not develop drug resistance. Obviously, the preparation should be most safe for human use both on earth and in space.

As a result of multiple experiments, they managed to develop a preparation which when fighting microorganisms produces no adverse or by-effects on the human organism; moreover, it possesses a number of useful qualities: enhances local immunity, heals inflammatory processes, speeds up wound repair, etc. This newly-developed next generation preparation is MYRAMISTIN®, and it answers the highest efficacy and safety standards both in treatment and preventive care.

Many-sided research of MYRAMISTIN® qualities were conducted in leading laboratories of Russia, Sweden, and Germany. The preparation successfully passed clinical tests in the leading research centres and clinics, such as the N. V. Sklifosovski Research Institute for Emergency Aid (Moscow), the A. V. Vishnevski Surgery Institute under Russian Academy for Medical Sciences (Moscow), the Sechenov Moscow Medical Academy (Moscow), Clinical Research Otorhinolaryngology Centre under the RF Ministry of Health (Moscow), Medical Academy for Postgraduate Education (Saint-Petersburg), the A. A. Bogomol'tsa National Medical University (Kiev), Dagestan National Medical Academy (Makhachkala), the Institute for General and Emergency Surgery (Kharkov), the S. I. Georgievski Crimean National Medical University (Simferopol), Research Institute for Virology and Epidemiology (Odessa), the D. I. Ivanovski Virology Institute under Russian Academy for Medical Sciences (Moscow), the A. N. Bakulev Institute for Cardiovascular Surgery (Moscow), and many others.

Studying MYRAMISTIN® resulted in more than 300 research papers (dissertations, patents, articles, guidelines, etc.).

MYRAMISTIN® belongs to cationic surfactants, namely, to quaternary ammonium compounds. Through numerous clinical and scientific researches it has been proved that MYRAMISTIN® is highly active to bacteria, fungi, viruses, and protozoa, including hospital multiresistant strains and microbial associations; local immunity strengthening and regeneration enhancement qualities of MYRAMISTIN® have also been proved, in addition, absence of harmful effects on human tissues has also been confirmed. Such combination of qualities makes MYRAMISTIN® a successful option for administration for both treatment and prevention of different etiology and localization inflammatory diseases.



Wide range antimicrobial effect including antibiotic-resistant hospital strains:

  • MYRAMISTIN® has express bactericidal effect and fights both gram-positive and gram-negative, aerobic and anaerobic, sporogenous and asporogenic bacteria; it is efficient both against pure cultures and microbial associations and even antibiotic-multiresistant hospital strains;
  • Has a fungicidal action against ascomycetes of genera Aspergillus and Penicillium, yeast fungi (Rhodotorula rubra, Torulopsis gabrata, etc.), yeast-like fungi (Candida albicans, Candida tropicalis, Candida krusei, etc.), dermatophytes (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton schoenleini, Trichophyton violacent, Epidermophyton Kaufman-Wolf, Epidermophyton floccosum, Microsporum gypseum, Microsporum canis, etc.), and many other pathogenic fungi, for example, Pityrosporum orbiculare (Malassezia furfur), both as pure cultures and microbial associations, including chemotherapy-resistant fungal florula;
  • Has an antiviral action; especially active against complex viruses (influenza, herpes, measles, scarlet fever, parotitis, smallpox, Aden fever, adenoviruses, etc.);
  • Decreases activity of human immunodeficiency virus 1,000 times (!);
  • Fights protozoa (chlamydiae, trichomonads, etc.);
  • Increases mycobacteria sensitivity to antituberculous preparations.


Increases bacteria, fungi and protozoa sensitivity to antibiotics:

  • MYRAMISTIN® synergy with antibiotics and other preparations shortens time of therapy and increases its efficiency.


Selective action:

  • Efficiently fights pathogenic microorganisms causing no harm to human body tissues.


Strengthens local immunity:

  • Stimulates defense response in the place of administration by activating phagocytes' scavenging and digesting activity;
  • Potentiates monocytic and macrophage activity.


Normalizes transport function of ciliated epithelium (mucociliary clearance):

  • Optimizes processes of lipid peroxidation when administered intrabronchially in patients with bronchus and lungs pathology.


Enhances regeneration processes:

  • Stimulates and speeds-up epithelization and wounds repair.


Acts anti-inflammatory:

  • Activates clot lysis in the inflammatory tissue.


Does not soak in and has no adverse effect on mucous coats and skin tissues.

No mutagenic, carcinogenic, or embryotoxic action. MYRAMISTIN® treatment of chronic diseases shortens time of therapy, decreases number of back-sets, prolongs remissions.

No allergic or locally irritating action:

  • Administration of MYRAMISTIN® causes no soreness;
  • In some cases, there may be a short-time sensation of burn, but it is not hazardous, passes off by itself and does not require cessation of the therapy.


MYRAMISTIN® is efficient both by itself and when taken with other preparations. MYRAMISTIN® is a colourless transparent liquid forming foam on its surface when shaken. MYRAMISTIN® is tasteless and odourless, although some individuals may taste it as slightly bitter.

Freezing or heating does not kill qualities of MYRAMISTIN®.

MYRAMISTIN® is released in the following forms and volumes:

  • 50 ml with a special cap;
  • 150 ml with a pulverizer.


MYRAMISTIN® is released ready-to use; it does not require dilution.

Shelf life is 3 years


Surgery, traumatic surgery:

  • Initial surgical debridement;
  • Pyoinflammatory processes in soft tissues and locomotor apparatus (furunculus, apostasis, phlegmon, panaris, peritonitis, central osteitis, etc.)
  • Trophic ulcers;
  • Bed sores;
  • Prophylaxis of pyoinflammatory complications, pre- and postoperative.


Burns surgery:

  • First to four degree burns (thermal, chemical, radioactive);
  • Burns contamination prophylaxis and treatment of infected burn-induced wounds;
  • Treatment of respiratory ways burns;
  • Dermatoplasty (pre- and postoperative administration).


Oral surgery, odontology:

  • Initial surgical debridement;
  • Pyoinflammatory processes in maxillo-facial area;
  • Inflammatory diseases in the oral cavity (stomatitis, parodontitis, gingivitis, etc.);
  • Oral cavity sanation prior to treatment and operations;
  • Root canals and cavities therapy (prior to temporary filling);
  • Prophylaxis of inflammatory complications, pre- and postoperative and in prosthetic repairs.



  • Prophylaxis of inflammatory complications before and after injection methods administration (mesoderm therapy, contour plastic reconstruction, etc.);
  • Prophylaxis of inflammations before and after piercing, depilation, tattooing and permanent makeup;
  • Prophylaxis and treatment of inflammations before and after manicure and pedicure.



  • Pyoinflammatory diseases of auris media, acoustic duct, pneumatic spaces, hypopharynx, and air-tube, by itself and in combination with other preparations;
  • Acute and chronic tonsillitis, pharyngitis, and laryngitis;
  • Pyogenic sinusitis (sinus trouble, frontal sinusitis, ethmoiditis, etc.);
  • Otopyosis, including cases complicated with rupture in the drum membrane;
  • Paratonsillar abscess and phlegmon;
  • Mechanical, thermal and chemical damage of ENT mucous coats;
  • Prophylaxis of pyoinflammatory complications, pre- and postoperative.


Therapy, Pediatrics, Pulmonology, Phthisiology:

  • Prophylaxis and treatment of inflammations in upper respiratory tracts;
  • Prophylaxis and treatment of virus diseases (influenza, acute respiratory virus infection, herpes, etc.);
  • Used in 3 to 14 y. o. patients as the basic remedy against acute pharyngitis and recrudescence of adenoid disease;
  • Tubercular endobronchitis (as a locally administered drug in combination with antituberculous preparations).


Obstetrics, gynecology:

  • Prophylaxis and treatment of pyoinflammations in parturient traumas, wounds of crotch and vagina, and obstetric infections;
  • Prophylaxis and treatment of pyoinflammations in minor gynaecological operations (erosion and polypus coagulation, abortion, and intrauterine device introduction or extraction);
  • Treatment of inflammatory bacterial, virus, and mycotic diseases (vaginitis, vulvovaginitis, endometritis, cervicitis, etc.);
  • Prophylaxis of inflammations in diagnostic manipulations;
  • Treatment and prophylaxis of sexually transmitted diseases.



  • In combination with other preparations in treatment of acute and chronic inflammatory diseases of specific and heterospecific etiology (urethritis, cystitis, prostatitis, urethroprostatitis, balanoposthitis, etc.);
  • Infection prophylaxis before and after diagnostic manipulations and at a long-term cannulation;
  • Inflammatory complications prophylaxis in urological operations.



  • Proctitis, sigmoiditis;
  • Acute and chronic paraproctitis;
  • Perianal fistulae;
  • Anoscopy, rectoromanoscopy (infection prophylaxis of wounds caused by diagnostic manipulations);
  • Anal fissures;
  • Coccygeal epithelial duct.



  • Pustular skin illnesses- staphyloderma and streptoderma (osteofolliculitis, epifolliculitis, sycosis, phlyctena, Fox's impetigo, bridoe, simple agria, ecthyma, impetigo vulgaris);
  • Dermatoses complicated with secondary bacterial or mycotic infections;
  • Skin allergic diseases (atopic eczema, eczema, etc.) brought about by glucocorticosteroids treatment;
  • Acne;
  • Individual prophylaxis of sexually transmitted diseases (syphilis, trichomoniasis, chlamidiosis, genital herpes, genital candidiasis, etc.);
  • Sexually transmitted diseases (as a locally administered preparation in combination with other treatments). MYRAMISTIN® is the leader in sexually transmitted diseases prophylaxis.


  • This personal hygiene aid is used to sustain healthy hygiene of skin and mucous coats, including those of private parts, as well as for hygienic application after visiting public swimming pools, baths and bathing sites.
  • Does not irritate skin.
  • Contains no alcohol or colourants.
  • Chemical group - quaternary ammonium compound.